Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2019 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VENTYX BIOSCIENCES INC | 11 | Q2 2024 | 37.8% |
KEZAR LIFE SCIENCES INC | 11 | Q2 2024 | 12.9% |
ICOSAVAX INC | 9 | Q4 2023 | 50.7% |
JASPER THERAPEUTICS INC | 9 | Q4 2023 | 21.1% |
HILLEVAX INC | 9 | Q2 2024 | 15.4% |
ELEVATION ONCOLOGY INC | 9 | Q4 2023 | 6.6% |
TALARIS THERAPEUTICS INC | 8 | Q3 2023 | 27.1% |
KORRO BIO INC | 3 | Q2 2024 | 36.9% |
TOURMALINE BIO INC | 3 | Q2 2024 | 18.9% |
JASPER THERAPEUTICS INC | 2 | Q2 2024 | 40.1% |
View Qiming U.S. Ventures Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-30 |
13F-HR | 2024-08-13 |
13F-HR | 2024-05-14 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-09 |
13F-HR | 2023-07-24 |
13F-HR | 2023-04-25 |
13F-HR | 2023-01-24 |
13F-HR | 2022-11-08 |
13F-HR | 2022-07-22 |
View Qiming U.S. Ventures Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.